Wang Mo-Jin, Ping Jie, Li Yuan, Holmqvist Annica, Adell Gunnar, Arbman Gunnar, Zhang Hong, Zhou Zong-Guang, Sun Xiao-Feng
From the Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China (M-JW, Z-GZ, X-FS); Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (M-JW, JP, AH, GA, X-FS); Department of Paediatric Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China (YL); Department of Surgery, and Department of Clinical and Experimental Medicine, Linköping University, Norrköping (GA); and School of Medicine, Örebro University, Örebro, Sweden (HZ).
Medicine (Baltimore). 2015 Dec;94(51):e2350. doi: 10.1097/MD.0000000000002350.
Mucinous adenocarcinoma (MC) is a special histology subtype of colorectal adenocarcinoma. The survival of MC is controversial and the prognostic biomarkers of MC remain unclear. To analyze prognostic significance and molecular features of colorectal MC. This study included 755,682 and 1001 colorectal cancer (CRC) patients from Surveillance, Epidemiology, and End Results program (SEER, 1973-2011), and Linköping Cancer (LC, 1972-2009) databases. We investigated independently the clinicopathological characteristics, survival, and variety of molecular features from these 2 databases. MC was found in 9.3% and 9.8% patients in SEER and LC, respectively. MC was more frequently localized in the right colon compared with nonmucinous adenocarcinoma (NMC) in both SEER (57.7% vs 37.2%, P < 0.001) and LC (46.9% vs 27.7%, P < 0.001). Colorectal MC patients had significantly worse cancer-specific survival (CSS) than NMC patients (SEER, P < 0.001; LC, P = 0.026), prominently in stage III (SEER, P < 0.001; LC, P = 0.023). The multivariate survival analysis showed that MC was independently related to poor prognosis in rectal cancer patients (SEER, hazard ratios [HR], 1.076; 95% confidence intervals [CI], 1.057-1.096; P < 0.001). In LC, the integrated analysis of genetic and epigenetic features showed that that strong expression of PINCH (HR, 3.954; 95% CI, 1.493-10.47; P = 0.013) and weak expression of RAD50 (HR 0.348, 95% CI, 0.106-1.192; P = 0.026) were significantly associated with poor CSS of colorectal MC patients. In conclusion, the colorectal MC patients had significantly worse CSS than NMC patients, prominently in stage III. MC was an independent prognostic factor associated with worse survival in rectal cancer patients. The PINCH and RAD50 were prognostic biomarkers for colorectal MC patients.
黏液腺癌(MC)是结直肠癌的一种特殊组织学亚型。MC患者的生存率存在争议,其预后生物标志物仍不明确。为分析结直肠MC的预后意义和分子特征。本研究纳入了来自监测、流行病学和最终结果计划(SEER,1973 - 2011年)和林雪平癌症(LC,1972 - 2009年)数据库的755682例和1001例结直肠癌(CRC)患者。我们分别从这两个数据库独立调查了临床病理特征、生存率和多种分子特征。在SEER和LC数据库中,分别有9.3%和9.8%的患者被诊断为MC。与非黏液腺癌(NMC)相比,MC在SEER(57.7%对37.2%,P < 0.001)和LC(46.9%对27.7%,P < 0.001)中更常位于右半结肠。结直肠MC患者的癌症特异性生存率(CSS)显著低于NMC患者(SEER,P < 0.001;LC,P = 0.026),在III期患者中尤为明显(SEER,P < 0.001;LC,P = 0.023)。多因素生存分析显示,MC与直肠癌患者的不良预后独立相关(SEER,风险比[HR],1.076;95%置信区间[CI],1.057 - 1.096;P < 0.001)。在LC中,基因和表观遗传特征的综合分析表明,PINCH的强表达(HR,3.954;95% CI,1.493 - 10.47;P = 0.013)和RAD50的弱表达(HR 0.348,95% CI,0.106 - 1.192;P = 0.026)与结直肠MC患者的不良CSS显著相关。总之,结直肠MC患者的CSS显著低于NMC患者,在III期患者中尤为明显。MC是直肠癌患者生存预后较差的独立预后因素。PINCH和RAD50是结直肠MC患者的预后生物标志物。